The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
Open accessAbstract
BACKGROUND: Hormone therapy for early prostate cancer has demonstrated an improvement in clinical and pathological variables, but not always an improvement in overall survival. We performed a systematic review of both adjuvant and neo-adjuvant hormone therapy combined with surgery or radiotherapy in localised or locally advanced prostate cancer. OBJECTIVES: The objective of this review was to undertake a systematic review and, if possible, a meta-analysis of neo-adjuvant and adjuvant hormone therapy in localised or locally advanced prostate cancer. SEARCH STRATEGY: We searched MEDLINE (1966-2006), EMBASE, The Cochrane Library, Science Citation Index, LILACS, and SIGLE for relevant randomised trials. Handsearching of appropriate publications was also undertaken. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials of patients with localised or locally advanced prostate cancer, that is, stages T1-T4, any N, M0, comparing neo-adjuvant or adjuvant hormonal deprivation in combination with primary therapy (radical radiotherapy or radical prostatectomy) versus primary therapy alone were included in this review. DATA COLLECTION AND ANALYSIS: Data were extracted from eligible studies and assessed for quality, and included information on study design, participants, interventions, and outcomes. Comparable data were pooled together for meta-analysis with intention-to treat principle. MAIN RESULTS: Men with prostate cancer have different clinical outcomes based on their risk (T1-T2, T3-T4, PSA levels and Gleason score). However, the majority of studies included in this review did not report results by risk groups; therefore, it was not possible to perform sub-group analysis. Neo-adjuvant hormonal therapy prior to prostatectomy did not improve overall survival (OR 1.11, 95% CI 0.67 to 1.85, P = 0.69). However, there was a significant reduction in the positive surgical margin rate (OR 0.34, 95% CI 0.27 to 0.42, P < 0.00001) and a significant improvement in other pathological variables such as lymph node involvement, pathological staging and organ confined rates. There was a borderline significant reduction of disease recurrence rates (OR 0.74, 95% CI 0.55 to 1.0, P = 0.05), in favour of treatment. The use of longer duration of neo-adjuvant hormones, that is either 6 or 8 months prior to prostatectomy, was associated with a significant reduction in positive surgical margins (OR 0.56, 95% CI 0.39 to 0.80, P = 0.002). In one study, neo-adjuvant hormones prior to radiotherapy significantly improved overall survival for Gleason 2 to 6 patients; although, in two studies, there was no improvement in disease-specific survival (OR 0.99, 95% CI 0.75 to 1.32, P = 0.97). However, there was a significant improvement in both clinical disease-free survival (OR 1.86, 95% CI 1.93 to 2.40, P < 0.00001) and biochemical disease-free survival (OR 1.93, 95% CI 1.45 to 2.56, P < 0.00001). Adjuvant androgen deprivation following prostatectomy did not significantly improve overall survival at 5 years (OR 1.50, 95% CI 0.79 to 2.85, P = 0.2); although one study reported a significant disease-specific survival advantage with adjuvant therapy (P = 0.001). In addition, there was a significant improvement in disease-free survival at both 5 years (OR 3.73, 95%CI 2.30 to 6.03, P < 0.00001) and 10 years (OR 2.06, 95% CI 1.34 to 3.15, P = 0.0009). Adjuvant therapy following radiotherapy resulted in a significant overall survival gain apparent at 5 (OR 1.46, 95% CI 1.17 to 1.83, P = 0.0009) and 10 years (OR 1.44, 95% CI 1.13 to 1.84, P = 0.003); although there was significant heterogeneity (P = 0.09 and P = 0.07, respectively). There was also a significant improvement in disease-specific survival (OR 2.10, 95% CI 1.53 to 2.88, P = 0.00001) and disease-free survival (OR 2.53, 95% CI 2.05 to 3.12, P < 0.00001) at 5 years. AUTHORS' CONCLUSIONS: Hormone therapy combined with either prostatectomy or radiotherapy is associated with significant clinical benefits in patients with local or locally advanced prostate cancer. Significant local control may be achieved when given prior to prostatectomy or radiotherapy, which may improve patient's quality of life. When given adjuvant to these primary therapies, hormone therapy, not only provides a method for local control, but there is also evidence for a significant survival advantage. However, hormone therapy is associated with significant side effects, such as hot flushes and gynaecomastia, as well as cost implications. The decision to use hormone therapy should, therefore, be taken at a local level, between the patient, clinician and policy maker, taking into account the clinical benefits, toxicity and cost. More research is needed to guide the choice, the duration, and the schedule of hormonal deprivation therapy, and the impact of long-term hormone therapy with regard to toxicity and the patient's quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Pilepich, M. V., Winter, K., John, M. J., Mesic, J. B., Sause, W., Rubin, P., Lawton, C., Machtay, M., & Grignon, D. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01579-6 · Cited by 772
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Hanks, G. E., Pajak, T. F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E. M., Lawton, C., Rosenthal, S. A., Sandler, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.023 · Cited by 689
Pilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B., Hanks, G. E., Coughlin, C. T., Porter, A., Shipley, W. U., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1013 · Cited by 607
Pilepich, M. V., Sause, W. T., Shipley, W. U., Krall, J. M., Lawton, C. A., Grignon, D., Al-Sarraf, M., Abrams, R. A., Caplan, R., John, M. J., et al. (1995) · Urology · doi:10.1016/s0090-4295(99)80053-3 · Cited by 487
Radical Cystectomy for Carcinoma of the Bladder: Critical Evaluation of the Results in 1,026 Cases
Ghoneim, M. A., El-Mekresh, M. M., El-Baz, M. A., Elattar, I. A., & Ashamallah, A. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64487-2 · Cited by 447
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 375
Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E., Coughlin, C. T., & Pilepich, M. V. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01516-9 · Cited by 374
Moher, Cook, Jadad, Tugwell, Moher, Jones, Pham, & Klassen (1999) · Health Technology Assessment · doi:10.3310/hta3120 · Cited by 368
SOLOWAY, M. S., PAREEK, K., SHARIFI, R., WAJSMAN, Z., McLEOD, D., WOOD, D. P., PURAS-BAEZ, A., & THE LUPRON DEPOT NEOADJUVANT PROSTATE CANCER STUDY GROUP† (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)65393-1 · Cited by 341
GLEAVE, M. E., GOLDENBERG, S. L., CHIN, J. L., WARNER, J., SAAD, F., KLOTZ, L. H., JEWETT, M., KASSABIAN, V., CHETNER, M., DUPONT, C., et al. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65971-x · Cited by 326
Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P. J., & Puras-Baez, A. F. T. L. D. N. P. C. S. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67067-8 · Cited by 323
Laverdière, J., Gomez, J., Cusan, L., Raul Suburu, E., Diamond, P., Lemay, M., Candas, B., Fortin, A., & Labrie, F. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00513-5 · Cited by 309
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group (2006) · BJU International · doi:10.1111/j.1464-410x.2005.06051.x · Cited by 277
Schulman, C. C., Debruyne, F. M. J., Forster, G., Selvaggi, F. P., Zlotta, A. R., & Witjes, W. P. J. (2000) · European Urology · doi:10.1159/000020366 · Cited by 246
See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D. M. A., et al. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64652-6 · Cited by 230
GRANFORS, T., MODIG, H., DAMBER, J.-E., & TOMIC, R. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63235-x · Cited by 218
WIRTH, M. P., SEE, W. A., McLEOD, D. G., IVERSEN, P., MORRIS, T., CARROLL, K., & ON BEHALF OF THE CASODEX EARLY PROSTATE CANCER TRIALISTS' GROUP (2004) · Journal of Urology · doi:10.1097/01.ju.0000140159.94703.80 · Cited by 209
Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D., Hudson, P., Jackson, C. L., Romas, N. A., Patterson, L., et al. (1998) · Urology · doi:10.1016/s0090-4295(98)00184-8 · Cited by 202
KLOTZ, L. H., GOLDENBERG, S. L., JEWETT, M. A. S., FRADET, Y., NAM, R., BARKIN, J., CHIN, J., CHATTERJEE, S., & THE CANADIAN URO-ONCOLOGY GROUP (2003) · Journal of Urology · doi:10.1097/01.ju.0000081404.98273.fd · Cited by 199
'Early warning systems' for identifying new healthcare technologies.
Robert, Stevens, & Gabbay (1999) · Health Technology Assessment · doi:10.3310/hta3130 · Cited by 189
Lawton, C. A., Winter, K. A., Grignon, D. J., & Pilepich, M. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.141 · Cited by 161
Van Poppel, H., De Ridder, D., Elgamal, A. A., Van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G., Baert, L., & Members of the Belgian Uro-Oncological Study Group (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67068-x · Cited by 161
Hanks, G. E., Lu, J., Machtay, M. X., Venkatesan, V. M., Pinover, W. H., Byhardt, R. W., & Rosenthal, S. A. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)80021-8 · Cited by 153
Goldenberg, S. L., Klotz, L. H., Srigley, J. R., et al. (1996) · PubMed · Cited by 150
Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R. E., Diamond, P., Candas, B., & Labrie, F. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199601000-00010 · Cited by 150
Witjes, W. P. J., Schulman, C. C., & Debruyne, F. M. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00171-4 · Cited by 138
de Leval, J., Boca, P., Youssef, E., Nicolas, H., Jeukenne, M., Seidel, L., Bouffioux, C., Coppens, L., Bonnet, P., Andrianne, R., et al. (2002) · Clinical Prostate Cancer · doi:10.3816/cgc.2002.n.018 · Cited by 136
Laverdière, J., Nabid, A., de Bedoya, L. D., Ébacher, A., Fortin, A., Wang, C. S., & HAREL, F. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000112979.97941.7f · Cited by 130
Goldenberg, S. L., Klotz, L. H., Srigley, J. R., et al. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)65645-3 · Cited by 125
Crook, J. M., Ludgate, C. M., Malone, S. C., Lim, J. T. W., Perry, G., Eapen, L., Bowen, J., Robertson, S., & Lockwood, G. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.02.022 · Cited by 112
Iversen, P., Johansson, J., Lodding, P., Lukkarinen, O. A., Lundmo, P. I., Klarskov, P., Tammela, T. L. J., Taşdemir, İ., Morris, T., Carroll, K., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000139719.99825.54 · Cited by 98
Labrie, F., Bélanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Neoadjuvant hormonal therapy: The Canadian experience
Labrie, F., Cusan, L., Gomez, J., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00170-2 · Cited by 92
Horwitz, E. M., Winter, K. A., Hanks, G. E., Lawton, C. A., Russell, A. H., & Machtay, M. X. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01443-7 · Cited by 86
Lawton, C. A., Winter, K. A., Byhardt, R. W., Sause, W. T., Hanks, G. E., Russell, A. H., Rotman, M., Porter, A. T., McGowan, D. G., DelRowe, J. D., et al. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00288-5 · Cited by 85
Dalkin, B. L., Ahmann, F. R., Nagle, R. B., et al. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)66266-9 · Cited by 82
Akaza, H. (2004) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyh001 · Cited by 80
Akakura, K., Isaka, S., Akimoto, S., Itô, H., Okada, K., Hachiya, T., Yoshida, O., Arai, Y., Usami, M., Kotake, T., et al. (1999) · Urology · doi:10.1016/s0090-4295(99)00106-5 · Cited by 75
Tyrrell, C., Payne, H. A., See, W. A., McLeod, D. G., Wirth, M. P., Iversen, P., Armstrong, J. M., & Morris, C. D. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.005 · Cited by 70
Prezioso, D., Lotti, T., Polito, M., & Montironi, R. (2004) · Urologia Internationalis · doi:10.1159/000077113 · Cited by 64
Hugosson, J., Abrahamsson, P., Ahlgren, G., et al. (1996) · European Urology · doi:10.1159/000473789 · Cited by 57
Zagars, G. K., Pollack, A. S., & Smith, L. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00089-9 · Cited by 53
Ahlegren, G., Pedersen, K., Lundberg, S., Aus, G., Hugosson, J., & Abrahamsson, P. (2000) · Urology · doi:10.1016/s0090-4295(00)00838-4 · Cited by 47
Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer
Bolla, M. (1999) · European Urology · doi:10.1159/000052303 · Cited by 41
Cookson, M. S., Sogani, P. C., Russo, P., et al. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00022.x · Cited by 39
Konski, A. A., Sherman, E. J., Krahn, M. D., Bremner, K. E., Beck, J. R., Bruner, D. W., & Pilepich, M. V. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.010 · Cited by 39
Akaza, H., Homma, Y., Okada, K., Yokoyama, M., Usami, M., Hirao, Y., Tsushima, T., Ohashi, Y., Aso, Y., & The Prostate Cancer Study Group (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04014.x · Cited by 35
Lamb, D. S., Denham, J. W., Mameghan, H., Joseph, D. J., Turner, S., Matthews, J., Franklin, I., Atkinson, C. H., North, J., Poulsen, M. G., et al. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(03)00193-2 · Cited by 35
Chang, S. S., Reuter, V. E., Heston, W. D. W., Hutchinson, B., Grauer, L. S., & Gaudin, P. B. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<407::aid-cncr23>3.0.co;2-0 · Cited by 33
Konski, A. A., Bruner, D. W., Brereton, H. D., Feigenberg, S. J., & Hanks, G. E. (2005) · Cancer · doi:10.1002/cncr.21575 · Cited by 30
Effect of Total Androgen Ablation on Pathologic Stage and Resection Limit Status of Prostate Cancer
Montironi, R., Diamanti, L., Santinelli, A., Galetti-Prayer, T., Zattoni, F., Selvaggi, F. P., Pagano, F. C., & Bono, A. V. (1999) · Pathology - Research and Practice · doi:10.1016/s0344-0338(99)80036-3 · Cited by 21
Debruyne, F. M. J., Witjes, W. P. J., Schulman, C. C., et al. (1994) · European Urology · doi:10.1159/000475423 · Cited by 19
Jani, A. B., Kao, J., & Hellmän, S. (2003) · Cancer · doi:10.1002/cncr.11804 · Cited by 16
Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer
Homma, Y., Akaza, H., Okada, K., Yokoyama, M., Usami, M., Hirao, Y., Tsushima, T., Sakamoto, A., Ohashi, Y., Aso, Y., et al. (2004) · International Journal of Urology · doi:10.1111/j.1442-2042.2003.00781.x · Cited by 15
Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863
Zurlo, A., Collette, L., van Tienhoven, G., Blank, L. E. C. M., Warde, P. R., Dubois, J. B., Jeanneret, W., Storme, G. A., Bernier, J., Kuten, A., et al. (2002) · European Urology · doi:10.1016/s0302-2838(02)00257-9 · Cited by 15
Samant, R. S., Dunscombe, P., & Roberts, G. (2003) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(02)00242-9 · Cited by 15
Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy.
Van Poppel, H., Ameye, F., Oyen, R., et al. (1992) · PubMed · Cited by 15
Asbell (1996) · doi:10.1002/(sici)1097-0045(199610)29:4<243::aid-pros5>3.0.co;2-c
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Self-citationHeidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Self-citationMohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Metadata
- Authors
- Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-10-18
- Volume
- 2010
- Issue
- 1
- Pages
- CD006019-CD006019
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1546246969
- Cited by
- 257
- References
- 68
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.